Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HTR1A | P08908 | 3/20 | 0.54 |
| ▸ | USP2 | O75604 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | KDM4C | Q9H3R0 | 3/20 | 0.41 |
| ▸ | KCNH2 | Q12809 | 2/20 | 0.39 |
| ▸ | GLA | P06280 | 1/20 | 0.39 |
| ▸ | ENPP2 | Q13822 | 1/20 | 0.39 |
| ▸ | MAPT | P10636 | 1/20 | 0.39 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.39 |
| ▸ | MTNR1B | P49286 | 2/20 | 0.39 |
| ▸ | DRD2 | P14416 | 1/20 | 0.39 |
| ▸ | DRD3 | P35462 | 1/20 | 0.39 |
| ▸ | NQO2 | P16083 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5479142 | 0.89 | HTR1A (0.54) | HTR1AKCNH2GLAENPP2MTNR1A | |
| SCHEMBL8103275 | 0.83 | HTR1A (0.56) | HTR1AUSP2CYP3A4KDM4CENPP2 | |
| SCHEMBL5173384 | 0.82 | HTR1A (0.48) | HTR1AENPP2MTNR1AMTNR1BNQO2 | |
| Hydrochloric Acid SCHEMBL8112970 | 0.82 | HTR1A (0.55) | HTR1AUSP2CYP3A4KDM4CENPP2 | |
| SCHEMBL5223865 | 0.81 | MTNR1A (0.63) | HTR1AMTNR1AMTNR1BNQO2 | |
| SCHEMBL5175307 | 0.81 | KDM4C (0.40) | HTR1AKDM4CMTNR1AMTNR1B | |
| SCHEMBL9464927 | 0.81 | HTR1A (0.63) | HTR1AUSP2CYP3A4KDM4CENPP2 | |
| SCHEMBL5229128 | 0.80 | HTR1A (0.53) | HTR1AUSP2CYP3A4KDM4CENPP2 | |
| SCHEMBL5172931 | 0.80 | HTR1A (0.56) | HTR1AUSP2CYP3A4KDM4CENPP2 | |
| SCHEMBL9464770 | 0.78 | HTR1A (0.67) | HTR1AUSP2CYP3A4KDM4CENPP2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1869013-A1 | SUBSTITUTED CHROMAN DERIVATIVES, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF ANTIPHLOGISTICS | Bayer Schering Pharma Aktiengesellschaft (DE) | 2007-12-26 | — | — | EP | disclosed |
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | SCHERING AG (DE) | 2007-06-07 | — | — | US | disclosed |
| WO-2006108711-A1 | SUBSTITUTED CHROMAN DERIVATIVES, METHOD FOR THE PRODUCTION AND THE USE THEREOF IN THE FORM OF ANTIPHLOGISTICS | BAYER SCHERING PHARMA AKTIENGESELLSCHAFT (DE) | 2006-10-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070129358-A1 | Sbstituted chroman derivatives, processes for their preparation and their use as antiinflammatory agents | TNF, CXCL8, MPO | HTR1A 660/4885USP2 3809/4885CYP3A4 69/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.